前列地尔注射液预防对比剂肾病的有效性研究  

Efficacy of alprostadil injection on prophylaxis of contrast-induced nephropathy

作　　者：熊宁[1] 彭志群[1] 刘俊[1] 王强[1] 吴珊燕[1] 陈传琳 邓丽娟[1] 

机构地区：[1]江西省鹰潭市解放军第一八四医院心内科,江西鹰潭335000

出　　处：《中国介入心脏病学杂志》2014年第2期89-91,共3页Chinese Journal of Interventional Cardiology

基　　金：2012年度南京军区科技创新课题(12MA054)

摘　　要：目的探讨前列地尔注射液对冠心病患者行冠状动脉造影引起对比剂肾病的预防作用。方法选择冠心病患者186例,分为两组:对照组93例(常规水化),试验组93例(前列地尔注射液+常规水化)。于冠状动脉造影前及术后24 h、48 h、72 h分别测定尿素氮、血清肌酸酐及肌酐清除率。并观察造影住院总死亡率。结果试验组和对照组的对比剂肾病发生率分别为3.2%(3/93)和11.8%(11/93),两组比较差异具有统计学意义(P<0.05)。结论行冠状动脉造影术患者使用前列地尔注射液可明显改善患者术后肾功能,降低对比剂肾病的发生率。Objective To explore the prophylaxis of alprostadil injection for contrast-induced nephropathy in patients who underwent coronary angiography. Methods 186 patients were randomly divided into 2 groups.In the control group （n=93）, the patients only accepted routine hydration treatment by intravenous of 0.9% sodium chloride solution. In the experimental group, besides the hydration treatment, the patients also accepted intravenous infusion of alprostadil injection. BUN, Scr and Ccr were detected before coronary angiography, and 24 hours, 48 hours, 72 hours after coronary angiography in all patients.And observe the rate of mortality. Results The patients in the experimental group and the control group experienced the incidence of contrast-induced nephropathy of 3.2% versus 11.8% （P 〈 0.05）, and the mortality of 0% versus 1.1% （P 〈 0.01）. Conclusions Application of alprostadil injection before coronary angiography could obviously improve the ranal functions of the patients, and significantly decrease the incidence of contrast- induced nephropathy.

关 键 词：前列地尔注射液 预防 对比剂肾病 

分 类 号：R541.4[医药卫生—心血管疾病]